Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on AKARI THERAPEUTICS PLC. We currently have 3 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
AKARI THERAPEUTICS PLC
AKARI THERAPEUTICS PLC
ASH data highlight Coversin's unique properties
09 Jan 17
Akari provided an update at the American Society of Hematology (ASH) meeting on the Soliris-resistant patient who has now been well controlled with Coversin for nine months. New data were released supporting a once-daily dosing, with complete inhibition of hemolysis with 22.5mg and 30mg per day. The company also provided guidance on new indications either by leveraging Coversin’s leukotriene B4 activity, or its ease of derivatization into new longer lasting and targeted versions. Results from the Phase II paroxysmal nocturnal hemoglobinuria study are expected in Q117.
Increasing evidence of Coversin activity
08 Jul 16
Akari released interim results from a Phase Ib dose-ranging study of Coversin in healthy volunteers. The trial was a double-blind, placebo-controlled study with six participants and showed complete inhibition of complement activity in the four patients on the active arm, receiving 30mg of Coversin dosed twice daily for two days followed by once daily for five days. The Phase Ib trial is designed to continue to other doses; the company stated that it will proceed with Phase II studies using the 30mg subcutaneous dose.
Set up to compete in the Soliris market and more
20 Jun 16
Akari is biopharmaceutical company advancing the clinical development of Coversin, a complement inhibitor derived from the saliva of a species of tick. Coversin shares a mechanism of action with the $2.59bn drug Soliris (Alexion, 2015 sales), and the company will be seeking approval for the same ultra-rare autoimmune hemolytic disorders as Soliris, as well as two other immune disorders without current treatments. The drug is currently in a dose ranging study and has successfully stabilized a Soliris resistant PNH patient in a Phase II trial. Akari plans to initiate three Phase II programs in 2016. We currently value Akari at $23.17 per ADS.
N+1 Singer - Morning Song 21-03-2017
21 Mar 17
accesso Technology (ACSO LN) Full year results in line, but key trading months still ahead | Augean (AUG LN) Double digit growth in ’16, good start to ‘17 | Earthport (EPO LN) Interims show continued top line strength | Goals Soccer Centres (GOAL LN) Good momentum under new team. It’s now all about delivery | IQE (IQE LN) FY’16 results prompt further upgrades | Microsaic Systems (MSYS LN) Challenges in 2016, strategy remains in place | mporium Group (MPM LN) Funds raised to help execute strategy | RhythmOne (RTHM LN) Dawn of the independents | ScS Group (SCS LN) Strong progress on key growth initiatives albeit comps now toughen | Sinclair Pharma (SPH LN) FY results: EBITDA ahead, Instalift™ gaining pace | Vectura Group (VEC LN) FY (9-month) results
N+1 Singer - EKF Diagnostics - Final results & potential buy back
20 Mar 17
FY16 prelims are slightly ahead of our latest expectations, those having been increased materially over the course of H2’16 as the strength of the recovery in trading became apparent. In order to maximise shareholder value, the directors are currently examining a potential break up of the group. This would also involve a delisting from AIM. A buy back offer at 21.5p would therefore be made to those investors that wish to exit now rather than holding their shares for the two years plus it would likely take to achieve a potentially higher realisation value for the businesses.
Good results, but further restructuring complex for investors
20 Mar 17
EKF Diagnostics FY 2016 results are slightly ahead of expectations, with both higher revenue and better EBITDA. Management has also announced plans to split the company into two separate companies, Point of Care and Laboratory Diagnostics, with the prospect of a delisting to manage the process. The primary metric for valuation of the two businesses is different consequently we believe that the separation is likely to generate significant value. However, in anticipation of the volatility likely given the restructuring announced this morning, despite the strength of the results, we reduce our recommendation to HOLD and maintain our 21p target price.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017